AGGXinactive

ANGIOGENEX, INC.

Healthcare·Oncology·Pre-clinical
OncologyOphthalmology

ANGIOGENEX, INC. (AGGX): 5 pipeline candidates. Updated within the last hour.

5.3/10

BioSniper Score

2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial HealthN/A

N/A

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for ANGIOGENEX, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

—

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (5 candidates)

DrugPhase
agx51Preclinical
agx51-αPreclinical
agx8Preclinical
agxaPreclinical
id-based diagnostic/prognostic productsPreclinical
·CEO: Robert Benezra

Frequently asked questions

How many drug candidates are in ANGIOGENEX, INC.'s pipeline?

ANGIOGENEX, INC. (AGGX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is ANGIOGENEX, INC.'s lead drug candidate?

ANGIOGENEX, INC.'s most advanced tracked candidate is agx51 (Preclinical) for Cancer.

Who is the CEO of ANGIOGENEX, INC.?

Robert Benezra is the chief executive officer of ANGIOGENEX, INC. (AGGX).

Get the full picture on ANGIOGENEX, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar